Y-mAbs Therapeutics (YMAB) Q4 2024 earnings summary

Executive summary

• Total revenue for 2024 was $87.7 million, within guidance, with DANYELZA net product revenues of $85.2 million and licensing revenue of $2.5 million.

• U.S. DANYELZA revenues declined due to unfavorable price mix and competition, while international DANYELZA sales grew 78% in Q4 and 16% for the year, especially in Asia and Latin America.

• Business realignment established two units: DANYELZA and Radiopharmaceuticals, to accelerate SADA PRIT platform development and maximize DANYELZA's potential.

• Ended 2024 with $67.2 million in cash and cash equivalents, supporting operations into 2027, with annual cash investment of $11.4 million, below guidance.

• Net loss for Q4 2024 was $6.8 million ($0.15/share), and for the year $29.7 million ($0.67/share), both higher than 2023 due to increased operating expenses and FX impacts.

Financial highlights

• Q4 2024 revenues were $26.5 million, up 13% year-over-year; FY 2024 revenues were $87.7 million, up 3% year-over-year.

• U.S. DANYELZA net product revenue: $16.8 million in Q4 (-12% YoY), $66.0 million for FY (-3% YoY); international DANYELZA: $7.7 million in Q4 (+78% YoY), $19.2 million for FY (+16% YoY).

• Gross profit: $18.9 million in Q4 (down from $21.3 million YoY); $72.7 million for FY (down from $73.5 million YoY), impacted by lower margins in Asia.

• Research and development expenses decreased to $49 million for 2024, while SG&A increased to $54.6 million, reflecting legal settlements and personnel costs.

• Gross margin: 71% in Q4 2024 (down from 91% YoY); 83% for FY 2024 (down from 87% YoY).

Outlook and guidance

• 2025 total net revenue guidance is $75–90 million; Q1 2025 revenue expected between $18–21 million.

• 2025 total net operating expenses (including COGS) expected at $129–134 million; excluding COGS, $116–121 million.

• Annual cash investments for 2025 projected at $25–30 million.

• Cash expected to fund operations into 2027.

• Guidance range reflects seasonality, stocking effects, and aims for realistic, achievable targets.